Evaluation of biomarkers associated with the clinical effect of the CIMAvax-EGF® vaccine in patients with advanced stages of non-small cell lung cancer (NSCLC). Exploratory Study of Biomarkers - EMA-Lung

Center of Molecular Immunology (CIM)0 个研究点目标入组 20 人开始时间: 2024年6月20日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Patients who have signed the informed consent for the research .
•2. Patients of any sex and older than 19 years.
•3. Patients who meet the diagnostic criteria.
•4. Patients with clinical status criteria (ECOG) of 0 a2.
•5. Patients who have achieved partial response or stable disease after the first line of onco-specific treatment.
•6. Patients with a life expectancy of 6 months or more.

•1. Patients of childbearing potential who are not using an adequate method of contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of the male sex (vasectomy, use of condoms) while the treatment lasts
•2. Pregnant, breastfeeding or postpartum patients.
•3. Patients who are participating in another clinical trial or who have been treated with specific immunotherapy with CIMAvax-EGF® in the previous 6 months.
•4. Patients with uncontrolled intercurrent diseases that include, but are not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes mellitus, arterial hypertension and psychiatric diseases that imply the incompetence of the subject.
•5. Patients with acute allergic states or history of severe allergic reactions.
•6. Patients with brain metastasis.

发起方

Center of Molecular Immunology (CIM)